Worst Biopharma CEO of 2024? It’s no contest

Remi Barbier, the former — and currently disgraced — CEO of Cassava Sciences, is the Worst Biopharma CEO of 2024. 

He’s also the easiest, most obvious selection I’ve ever made for this particular dishonor, something I’ve been doing annually for 17 years. 

Barbier had a bad year. Cassava’s Alzheimer’s drug candidate simufilam proved to be nothing more than a placebo in a large clinical trial. The company blew up. He lost his job. He was penalized by the Securities and Exchange Commission. And he remains a defendant in ongoing shareholder and class-action lawsuits. 

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$20

for 3 months, then $399/year

$20 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In